ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancer
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it will open a randomized, registration-enabling phase 2/3 clinical trial to evaluate ivonescimab combined with chemotherapy as first-line treatment for patients with advanced biliary tract cancer (BTC).
Read original article on The Medical News →Related news
-
France reports first human Shamonda virus case, says no health risk
United Kingdom
-
How L-carnitine, found in red meat and exercise supplements, may amplify inflammation
United Kingdom
-
Your brain maps out numbers, including integers and fractions
United Kingdom
-
Mental health support for parents after pediatric intensive care may modestly reduce PTSD and depressive symptoms
United Kingdom
-
Comprehensive DNA sequencing reveals hidden drivers of cancer
United Kingdom
-
Q&A: Expert explains why women should reconsider skipping the Pap smear
United Kingdom
-
'Molecular glue' stabilizes protein that inhibits development of non–small cell lung cancer and uterine cancer
United Kingdom
-
Male breast cancer: Risk rises with age, expert explains
United Kingdom